In a significant setback for the burgeoning field of psychedelic-assisted therapy, the Food and Drug Administration (FDA) recently issued a Complete Response Letter (CRL) to Lykos Therapeutics, rejecting their application for MDMA-assisted therapy for post-traumatic stress disorder (PTSD). This decision has sent ripples through the psychedelic and mental health communities, reigniting debates over the future of psychedelic therapies in mainstream medicine.
The FDA’s Decision and Lykos’ Response
The FDA’s CRL, issued on August 9, 2024, requested that Lykos conduct an additional Phase 3 trial to further assess the safety and efficacy of their MDMA-assisted therapy. Lykos had hoped that their existing data, which included results from prior Phase 3 studies, would be sufficient to secure approval. The FDA, however, cited concerns raised during an earlier advisory committee meeting, including issues related to expectancy bias and the necessity of psychotherapy in conjunction with MDMA treatment.
Lykos Therapeutics expressed deep disappointment in the FDA’s decision, with CEO Amy Emerson stating, “The FDA request for another study is deeply disappointing, not just for all those who dedicated their lives to this pioneering effort, but principally for the millions of Americans with PTSD, along with their loved ones, who have not seen any new treatment options in over two decades.” Emerson emphasized that while conducting another Phase 3 study would take years, the company plans to pursue all available regulatory pathways to address the FDA’s concerns and bring this potentially transformative treatment to the millions of Americans suffering from PTSD.
The Industry’s Response: Advocacy and Innovation
The FDA’s decision has sparked a wave of responses from across the psychedelic and mental health communities. Amber Capone, CEO and Co-Founder of VETS, an organization dedicated to providing psychedelic-assisted therapies to veterans, issued a passionate statement. She highlighted the dire need for new treatments to address the veteran suicide epidemic, with an estimated 20 to 44 veterans dying by suicide each day. “This development is merely another hurdle in our ongoing mission to end the veteran suicide epidemic,” Capone stated, vowing that VETS will continue to advocate for MDMA-assisted therapy and other innovative treatments.
Capone’s statement reflects a broader sentiment within the psychedelic industry: a determination to push forward despite regulatory setbacks. She emphasized that while the FDA’s commitment to safety is understood, the cost of inaction—measured in lives lost to untreated PTSD—is too high. VETS remains committed to conducting research, providing access to therapies abroad, and fighting for the approval of these treatments on U.S. soil.
”Decades of paternalism and moral panic have unjustly restricted access to a substance that could relieve millions suffering from PTSD. The overwhelming evidence supports the safety and efficacy of MDMA-assisted therapy, a promising option where current treatments fail. The benefits far outweigh the risks, making FDA approval a moral and pragmatic imperative. To deny this is to continue the state’s overreach into personal health decisions, perpetuating unnecessary suffering. ” said Sandeep Prakash, Ph.D. Co-Founder & Chief Scientific Officer at SoundSelf
The Challenges of Integrating Psychedelics into Traditional Medicine
Kathryn A. Walker, CEO of Revitalist, a company involved in psychedelic-assisted therapy, offered a perspective on the challenges of integrating MDMA and other psychedelics into the traditional medical framework. She noted that the FDA’s hesitance is partly due to the novel nature of these therapies, which combine medication with psychotherapy in ways that traditional drug approval processes are not designed to handle. “Psychedelics are here to break the mold,” Walker stated, “we have to understand we have to create the mold around the psychedelic as the drug was not meant to function in the same realm as our traditionally broken system.”
This sentiment underscores the broader challenge faced by the psychedelic industry: the need to advocate for new regulatory standards that recognize the unique nature of psychedelic-assisted therapies. Unlike conventional pharmaceuticals, which are typically evaluated as standalone treatments, psychedelics like MDMA are intended to be used in conjunction with psychotherapy, creating a complex therapeutic protocol that traditional FDA processes struggle to evaluate.
A Call for “Responsible Innovation”
Dr. Shauna Springer, Chief Psychologist at Stella, emphasized the need for what she calls “responsible innovation” in the field of psychedelic therapies. While advocating for the approval of MDMA-assisted therapy, Springer stressed that safety concerns must be thoroughly addressed. “The critical question isn’t whether the FDA should approve MDMA, but rather under what conditions it should be approved,” she stated. Springer suggested that innovative solutions, such as administering MDMA in inpatient settings with comprehensive medical and psychological support, could address many of the FDA’s concerns.
The Neuroplasticity Edge: MDMA’s Potential Impact
Shari B. Kaplan, a vocal advocate for MDMA’s potential in mental health treatment, highlighted the biochemical benefits of the drug that set it apart from traditional treatments. “The FDA should approve MDMA for mental health treatment because it offers an opportunity for people to heal in a very short period of time who are truly suffering,” Kaplan argued. She pointed out that what MDMA can accomplish in a five-hour session is often more impactful than what conventional pharmaceuticals achieve over weeks. “The neuroplasticity, dopamine, and oxytocin shifts that aid the patient in cultivating compassion for themselves, increasing awareness, and developing new positive thoughts and behaviors have been demonstrated in just three sessions of treatment,” she added.
Kaplan’s insights bring attention to the unique advantages of MDMA-assisted therapy, especially in its ability to facilitate rapid and profound therapeutic breakthroughs. However, she also cautioned that MDMA is not suitable for everyone, emphasizing the need for rigorous screening to avoid prescribing it to individuals with a potential for psychosis.
The Future of Psychedelic Medicine: Non-Hallucinogenic Alternatives
Dr. Joseph Tucker, CEO of Enveric Biosciences, provided a broader perspective on the challenges highlighted by the FDA’s decision. “The thematic challenges that came to light in the Lykos Adcomm largely focused around two elements, expectation bias and the delivery of the psychological therapy,” Tucker explained. He acknowledged that these issues are difficult to separate from any therapy that induces hallucinations and requires psychotherapy, but he also pointed to the emerging next generation of non-hallucinogenic neuroplastogens as a potential solution. Tucker speculated that these non-hallucinogenic compounds might eventually surpass traditional psychedelics in the field of neuropsychiatric medicine, offering similar therapeutic benefits without the complexities associated with hallucinogenic experiences.
Looking Forward: The Future of Psychedelic Therapies
Despite the setback, the psychedelic industry remains optimistic about the future of MDMA-assisted therapy and other psychedelic treatments. The rejection of Lykos’ application has highlighted the need for continued advocacy, rigorous research, and a willingness to adapt to the regulatory landscape.
Doug Drysdale, CEO of Cybin, a company developing psychedelic-based therapies, echoed this optimism. While acknowledging the disappointment of the FDA’s decision, Drysdale emphasized that it was not unexpected and that there remains strong regulatory support for the development of psychedelic drugs. He pointed to the importance of well-designed clinical trials and alignment with FDA guidance as crucial steps in overcoming these challenges.
As the psychedelic industry continues to navigate the complex regulatory environment, the commitment to providing innovative treatments for mental health conditions remains unwavering. The FDA’s rejection of MDMA-assisted therapy may be a setback, but for many in the field, it is seen as just another step in the long journey toward revolutionizing mental health care. As Capone aptly put it, “We are never out of the fight.”
